EU Publishes Second Revision of MDCG 2023-3: Key Updates for Manufacturers
The European Commission has released the second revision of the MDCG 2023-3 guidance document in January 2025. This update includes important clarifications in line with Regulation (EU) 2024/1860, affecting the implementation of Eudamed, post-market surveillance, and reporting timelines. Below, we summarize the key changes:
- Alignment with Regulation (EU) 2024/1860
Footnote 8 has been amended to align with Regulation (EU) 2024/1860, which introduces a gradual roll-out of Eudamed. Additionally, it clarifies the obligation to inform authorities in case of supply interruptions or discontinuations and provides transitional provisions for specific in vitro diagnostic medical devices (IVDs). - Terminology Update for Eudamed Vigilance Module
In Question 21, the reference to ‘Eudamed vigilance (VGL) module’ has been updated to ‘Eudamed Post-market surveillance and Vigilance module (VGL module)’. This change reflects a broader scope of post-market surveillance requirements within Eudamed. - Clarification on Reporting Timelines
Footnote 34 has been revised to replace ‘48 working hours’ with ‘allow 48 hours (equivalent to two weekdays)’. This clarification ensures a consistent interpretation of reporting deadlines.
These updates highlight the ongoing efforts of the European Commission to refine regulatory guidance and improve clarity for manufacturers and stakeholders.
For detailed information, refer to the full guidance document: MDCG 2023-3 Rev.2.
MedNet EC-REP GmbH remains committed to supporting medical device and IVD manufacturers in navigating regulatory changes. For questions regarding Eudamed requirements or compliance, feel free to contact us.
Latest news
Implications of the Update to the Borderline & Classification Manual under MDR and IVDR
On 12 September 2025, the European Commission published Version 4 of the Manual on Borderline and Classification under Regulations (EU) 2017/745 and 2017/746, developed by the Borderline and Classification Working Group (BCWG).
Regulatory Affairs Bulletin: Intended Purpose vs Intended Use under MDR & IVDR
European regulations EU 2017/745 (MDR) and EU 2017/746 (IVDR) require precise definitions in technical documentation, and the distinction (or overlap) between intended purpose and intended use remains a topic of operational significance.
-250x250.jpg&w=256&q=75)
MedNet EC-REP GmbH at MEDICA 2025 – Visit Us in Hall 3, Booth D43
MedNet EC-REP GmbH is pleased to announce that we will once again be exhibiting at MEDICA 2025 in Düsseldorf, the world’s leading trade fair for the medical technology industry.
EU eIFU Regulation Update Draft: What Medical Device Professionals Need to Know
The European Commission has introduced a significant amendment to Implementing Regulation (EU) 2021/2226, impacting how medical device manufacturers provide instructions for use (IFU).
Understanding the Interplay: MDR, IVDR, and the AI Act – Key Insights from MDCG 2025-6
Recently, the MDCG, in conjunction with the Joint Artificial Intelligence Board (AIB), released the MDCG 2025-6 FAQ document, offering essential clarifications on the interplay between the MDR, the IVDR, and the Artificial Intelligence Act (AIA).
Navigating IVDR and MDR Performance Studies: Key Insights from MDCG 2025-5 Q&A
The European Medical Device Coordination Group (MDCG) has released its latest guidance, MDCG 2025-5, a comprehensive Questions & Answers document addressing performance studies for in vitro diagnostic medical devices (IVDs) under Regulation (EU) 2017/746 (IVDR).
MDCG 2019-11 Rev.1: Important Changes for Medical Device Software Developers
In the dynamic world of medical device regulation, staying abreast of the latest guidance is paramount for manufacturers. The Medical Device Coordination Group (MDCG) has recently released a significant update to its MDCG 2019-11 guidance document, now designated as MDCG 2019-11 Rev.1.
MDCG 2025-4: Key Guidance for Medical Device Software on Online Platforms
The European Commission's Medical Device Coordination Group (MDCG) has released the MDCG 2025-4 guidance document, titled "Guidance on the safe making available of medical device software (MDSW) apps on online platforms."